185 related articles for article (PubMed ID: 36444392)
1. Characterization of health concerns in people with neurofibromatosis type 1.
Fleming J; Morgan O; Wong C; Schlub TE; Berman Y
Mol Genet Genomic Med; 2023 Jan; 11(1):e2077. PubMed ID: 36444392
[TBL] [Abstract][Full Text] [Related]
2. Development and preliminary evaluation of the Neurofibromatosis Type 1 Adult Quality of Life (NF1-AdQoL) questionnaire.
Crawford H; North K; Wilson MJ; Berman Y; McKelvey-Martin V; Morrison PJ; Fleming J; Barton B
Clin Exp Dermatol; 2022 Feb; 47(2):271-281. PubMed ID: 34342021
[TBL] [Abstract][Full Text] [Related]
3. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
[TBL] [Abstract][Full Text] [Related]
4. Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1.
Cieza Rivera AM; Lobato Fuertes C; Fernández-Villa T; Martín Sánchez V; Atallah I
Orphanet J Rare Dis; 2024 Feb; 19(1):85. PubMed ID: 38402381
[TBL] [Abstract][Full Text] [Related]
5. The Role of Appearance in Adolescents' Experiences of Neurofibromatosis Type 1: A Survey of Young People and Parents.
Barke J; Coad J; Harcourt D
J Genet Couns; 2016 Oct; 25(5):1054-62. PubMed ID: 27001554
[TBL] [Abstract][Full Text] [Related]
6. Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.
Page PZ; Page GP; Ecosse E; Korf BR; Leplege A; Wolkenstein P
Am J Med Genet A; 2006 Sep; 140(18):1893-8. PubMed ID: 16906549
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults.
Fertitta L; Bergqvist C; Armand ML; Moryousef S; Ferkal S; Jannic A; Ravaud P; Tran VT; Ezzedine K; Wolkenstein P
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1359-1366. PubMed ID: 35412677
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and Factors of Quality of Life Among Patients With Neurofibromatosis Type 1-Associated Craniofacial Plexiform Neurofibromas.
Ren JY; Gu YH; Wei CJ; Huang X; Xu XW; Gu B; Zan T; Wang ZC; Li QF
J Craniofac Surg; 2020; 31(2):347-350. PubMed ID: 31977693
[TBL] [Abstract][Full Text] [Related]
9. Psychosocial functioning, self-image, and quality of life in children and adolescents with neurofibromatosis type 1.
Cipolletta S; Spina G; Spoto A
Child Care Health Dev; 2018 Mar; 44(2):260-268. PubMed ID: 28776749
[TBL] [Abstract][Full Text] [Related]
10. Speech difficulties and patient health communication mediating effects on worry and health-related quality of life in children, adolescents, and young adults with Neurofibromatosis Type 1.
Varni JW; Nutakki K; Swigonski NL
Am J Med Genet A; 2019 Aug; 179(8):1476-1482. PubMed ID: 31081992
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L.
Yoshida Y; Ehara Y; Koga M; Imafuku S
J Dermatol; 2022 Dec; 49(12):1228-1232. PubMed ID: 35781730
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior.
Krab LC; Oostenbrink R; de Goede-Bolder A; Aarsen FK; Elgersma Y; Moll HA
J Pediatr; 2009 Mar; 154(3):420-5, 425.e1. PubMed ID: 18950800
[TBL] [Abstract][Full Text] [Related]
13. Uptake of health monitoring and disease self-management in Australian adults with neurofibromatosis type 1: strategies to improve care.
Crawford HA; Barton B; Wilson MJ; Berman Y; McKelvey-Martin VJ; Morrison PJ; North KN
Clin Genet; 2016 Mar; 89(3):385-91. PubMed ID: 26081173
[TBL] [Abstract][Full Text] [Related]
14. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1.
Hamoy-Jimenez G; Elahmar HA; Mendoza M; Kim RH; Bril V; Barnett C
Orphanet J Rare Dis; 2022 Feb; 17(1):40. PubMed ID: 35135568
[TBL] [Abstract][Full Text] [Related]
15. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
[TBL] [Abstract][Full Text] [Related]
16. Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants.
Oostenbrink R; Spong K; de Goede-Bolder A; Landgraf JM; Raat H; Moll HA
J Pediatr; 2007 Aug; 151(2):182-6, 186.e1-2. PubMed ID: 17643775
[TBL] [Abstract][Full Text] [Related]
17. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan.
Lai JS; Jensen SE; Patel ZS; Listernick R; Charrow J
Am J Med Genet A; 2017 Jan; 173(1):79-87. PubMed ID: 27666129
[TBL] [Abstract][Full Text] [Related]
18. Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge.
Oates EC; Payne JM; Foster SL; Clarke NF; North KN
Am J Med Genet A; 2013 Apr; 161A(4):659-66. PubMed ID: 23427176
[TBL] [Abstract][Full Text] [Related]
19. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.
Nutakki K; Varni JW; Swigonski NL
J Neurooncol; 2018 Apr; 137(2):337-347. PubMed ID: 29273891
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.
Crawford HA; Barton B; Wilson MJ; Berman Y; McKelvey-Martin VJ; Morrison PJ; North KN
J Genet Couns; 2015 Dec; 24(6):931-44. PubMed ID: 25894096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
